The New York Times has published a new article profiling the new market of well-made medications in India.
Anyone can find many articles and instances of cheap or fraudulent prescription drugs making it to patients in the USA. Recently India has made strides to improve their patent laws and the quality-control of the medications being produced in the country. Large pharmaceutical companies have begun to buy up smaller operations which has India “on track to grow about 13 percent this year, to just over $24 billion” according to the article. They report Glaxo-Smith Kline, Pfizer and Bristol-Myers are all operating in the middle east country.
Cheaper production of medications passes on to patients as more money in their wallets. In Heather Timmons’ article she quotes Jim Worrell, the chief executive of Pharma Services Network, as saying “There is a lot of good talent at a much lower price in India.” All plants that are producing drugs for the USA are still held to FDA standards in order to supply American patients with medications.
How do you feel about drugs manufactured or outsourced to other countries?
ProgressiveRX 